Judy Bijoux-Leist

Judy Bijoux-Leist
  • Associate Professor
  • Department: Counselor Education
  • Institution: West Chester University of Pennsylvania
  • Email: JBijoux-Leist@wcupa.edu

Research Interests

Relationship issuesfamilies and couplesIdentity developmentSocial justiceMood DisorderObsessive Compulsive DisorderGrief and LossComplex traumas

Opportunities

Work Study Positions Available: No

Grant Funded Positions Available: No

Course-Credit Research Opportunities Available: No

Volunteer Research Positions Available: No

List of Publications

  • A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study, Article, Aug 2023 Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment, Article, May 2023 Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study, Article, Apr 2023 Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability, Article, Dec 2022 T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy, Article, Nov 2022 Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary, Article, Aug 2022 022 Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data, Article, May 2022 Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial, Article, Apr 2022 Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study, Article, Mar 2022 Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary, Article, Jan 2022 Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial, Article, Aug 2021

Links